$MDT

Medtronic Recalls 135,875 Barbed Surgical Sutures Over Torn Sterile Packaging and Patients Already Treated Need Monitoring

Medtronic recalled 135,875 units of its V-Loc 90 Absorbable Wound Closure Device due to potential tears in sterile packaging, risking biocontamination. The FDA classified this as a Class 2 recall, and hospitals are advised to monitor patients treated with affected sutures for infections or vision issues. The recall spans 11 product codes and multiple countries, with distribution ongoing since July. No injuries have been reported, but patients with symptoms should contact their surgical teams.

Original reporting
Published Aug 27, 2026, 2:45 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 27, 2026, 3:25 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Medtronic Recalls 135,875 Barbed Surgical Sutures Over Torn Sterile Packaging and Patients Already Treated Need Monitoring — source image
Decision brief

The 30-second read

$MDTBearishLow
01

Why it matters

The recall introduces a liability risk and could prompt a modest share decline, but the overall financial impact is likely limited given the product's niche usage.

02

Market read

Recall may cause a short‑term negative bias for Medtronic and highlight regulatory risk in the medical‑device sector.

03

What to watch

Potential for increased demand for alternative sutures and competitors' market share gains.

Relevance 6/10Novelty 6/10Timing: today

Background

Medtronic's V‑Loc barbed sutures are widely used across general, gynecologic, and robotic surgeries. The FDA classified the recall as Class 2, indicating reversible health effects.

Company-level read

Ticker impact

$MDTBearishMedium confidence
Context

Medtronic announced a Class 2 recall of 135,875 V‑Loc 90 absorbable sutures due to possible sterile‑barrier tears, creating liability and demand‑impact risk.

Expected impact

Potential short‑term dip of 1‑2% pending further updates.

Evidence & confidence

Large‑cap medical device firms typically see modest share moves on product recalls; the scale is limited to a specific suture line.

Market effects

May raise scrutiny on surgical‑device manufacturers and could prompt tighter FDA oversight.

US hospitals and international distributors may temporarily halt use, affecting regional supply chains.

Recall spans 60+ countries, but impact is confined to Medtronic's suture segment.

Counterpoint

The recall is limited in scope and may be priced in; Medtronic's broader portfolio could offset any short‑term hit.

Key entities

  • Medtronic

    Manufacturer of the recalled V‑Loc sutures.

  • Covidien

    Original maker of the V‑Loc device, now part of Medtronic.

  • FDA

    Classified the recall as Class 2.

Related articles

$DHRMedAI 8/10

Danaher vs. Medtronic: Which Healthcare Recovery Story Has More Upside?

Danaher (DHR) and Medtronic (MDT) report recovery signs. DHR benefits from life sciences demand, with bioprocessing orders growing mid-teens. MDT shows highest annual revenue growth in 10 years, with Q4 revenue at $9.8B and FY26 at $36.4B. MDT's cardiac segment grew 78% globally, driven by cardiac ablation solutions. Both companies face challenges, with MDT's growth concentrated in a few platforms and DHR's revenue delayed into next year.

$MDTMedAI 8/10

Medtronic vs. Tenet Healthcare: Which Healthcare Stock Offers Better Long-Term Growth?

Medtronic (MDT) and Tenet Healthcare (THC) present distinct growth prospects. MDT reported its highest annual revenue growth in a decade, driven by cardiac ablation solutions and investments in innovation. THC saw a 52.2% increase in adjusted EPS and 6.8% revenue growth, with margin expansion in hospitals. Investors must choose between MDT's innovation-led recovery and THC's operational improvements.

$ISRGMed

Johnson & Johnson and Medtronic Enter the Fray, Squeezing Market Share as Intuitive Surgical Faces Its Biggest Challenge in Recent Years

Intuitive Surgical (ISRG) stock fell 30% in 2026 due to weak guidance, competition, and high valuations. Q2 revenue grew 19%, but full-year procedure growth guidance was below expectations. Competitors like Johnson & Johnson and Medtronic are entering the market, raising concerns about ISRG's market share. Analysts note high valuation multiples and slowing growth may pressure the stock further.